Equities Analysts Issue Forecasts for United Therapeutics Co.’s Q1 2024 Earnings (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) – Investment analysts at Leerink Partnrs raised their Q1 2024 earnings estimates for United Therapeutics in a research report issued on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now expects that the biotechnology company will earn $5.93 per share for the quarter, up from their prior forecast of $5.90. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $23.46 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q2 2024 earnings at $6.32 EPS and Q3 2024 earnings at $7.04 EPS.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 EPS for the quarter, beating the consensus estimate of $4.28 by $0.08. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The company had revenue of $614.70 million for the quarter, compared to analysts’ expectations of $575.01 million. During the same period last year, the firm posted $2.67 earnings per share. United Therapeutics’s revenue was up 25.1% compared to the same quarter last year.

UTHR has been the subject of a number of other reports. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and boosted their target price for the company from $213.00 to $215.00 in a research note on Monday, February 12th. SVB Leerink assumed coverage on United Therapeutics in a report on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price on the stock. Wells Fargo & Company raised their target price on United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research report on Thursday, March 7th. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. Finally, Wedbush reissued an “outperform” rating and issued a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $292.67.

United Therapeutics Stock Up 0.4 %

Shares of United Therapeutics stock opened at $237.93 on Thursday. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. United Therapeutics has a twelve month low of $204.44 and a twelve month high of $261.54. The company has a market cap of $11.20 billion, a price-to-earnings ratio of 11.99 and a beta of 0.52. The company’s 50 day moving average is $231.71 and its 200 day moving average is $228.55.

Insider Activity

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the sale, the executive vice president now owns 36,599 shares in the company, valued at approximately $7,880,130.69. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,756.70. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $215.31, for a total value of $1,291,860.00. Following the completion of the transaction, the executive vice president now owns 36,599 shares of the company’s stock, valued at $7,880,130.69. The disclosure for this sale can be found here. Insiders have sold a total of 129,790 shares of company stock valued at $30,528,633 in the last ninety days. Corporate insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. First Trust Direct Indexing L.P. grew its position in United Therapeutics by 38.0% in the first quarter. First Trust Direct Indexing L.P. now owns 2,107 shares of the biotechnology company’s stock worth $484,000 after acquiring an additional 580 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in shares of United Therapeutics by 153.5% in the 1st quarter. State of Alaska Department of Revenue now owns 16,557 shares of the biotechnology company’s stock valued at $3,802,000 after purchasing an additional 10,025 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of United Therapeutics by 0.3% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 101,042 shares of the biotechnology company’s stock worth $23,211,000 after purchasing an additional 338 shares during the period. MBM Wealth Consultants LLC increased its position in shares of United Therapeutics by 2.7% during the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock valued at $515,000 after purchasing an additional 59 shares during the last quarter. Finally, State of Michigan Retirement System raised its holdings in United Therapeutics by 2.5% during the 1st quarter. State of Michigan Retirement System now owns 12,232 shares of the biotechnology company’s stock valued at $2,810,000 after buying an additional 300 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.